|Dr. Noubar B. Afeyan Ph.D.||Co-founder & Chairman||N/A||N/A||1963|
|Dr. Balkrishan Gill||Pres, CEO & Director||N/A||N/A||1965|
|Mr. Jonathan Poole||CFO & Treasurer||334.79k||N/A||1975|
|Dr. Duncan McHale M.D., Ph.D.||Chief Medical Officer||N/A||N/A||1967|
|Dr. Mark Bodmer||Chief Scientific Officer and Pres of R&D||N/A||N/A||1958|
Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815, which are in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of atopic dermatitis, asthma, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases. The company is also involved in developing EDP150, a monoclonal microbial candidate, which is in Phase 1/2 clinical study for the treatment of colorectal cancer, triple-negative breast cancer, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. Evelo Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Evelo Biosciences, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 7; Compensation: 7.